Browsing Tag
paroxysmal nocturnal hemoglobinuria
4 posts
Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
NovelMed Therapeutics advances Ruxoprubart with Phase II PNH results and a subcutaneous trial. Discover how it could reshape the complement inhibitor market.
AstraZeneca signs $39bn deal to acquire Alexion Pharmaceuticals
In a landmark move that’s poised to shake up the world of immunology and rare disease treatments, AstraZeneca…
Alexion to acquire Achillion to strengthen rare diseases portfolio
Alexion acquisition of Achillion : Alexion Pharmaceuticals has agreed to acquire rival US pharma company Achillion Pharmaceuticals for…
Alexion bags Ultomiris EU approval for paroxysmal nocturnal hemoglobinuria
Ultomiris EU approval : Alexion Pharmaceuticals has secured approval from the European Commission (EC) for its C5 complement…